A meeting was held in Tashkent’s khokimiyat with the participation of representatives of the Italian medical company Kedrion biopharma. For almost 20 years, it has been active in the field of the production of drugs from blood and plasma, which are used in the treatment of hemophilia and immunodeficiency.
The parties discussed the prospects for the construction of a production line of a unique medical product, Blood Coagulability Factor VIII. The total cost of production is US$25 million. This amount is planned to spend not only on production capacity but also on the laboratory for the development of new products.
During the meeting, a memorandum of mutual cooperation was signed. It was proposed to form a working group to create a project commission.
